gentiopicroside has been researched along with Diabetic Glomerulosclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Huang, H; Lin, Z; Liu, P; Liu, R; Quan, S; Sun, X; Xiao, H; Yang, Y; Zhang, M | 1 |
1 other study(ies) available for gentiopicroside and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Diabetic Nephropathies; Iridoid Glucosides; Male; Mice, Inbred C57BL; NF-kappa B; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Signal Transduction | 2020 |